Logistics & Transportation

Articles

The $530 million investment will accelerate the company’s development and production process for therapies in the rare disease space. 

Senior Director of Strategic Planning at Marken.

New innovations that are contributing to industry environmental efforts. 


The development and manufacturing plant will be constructed in Texas, and is expected to become operational by Q1 2025.

The new plant in Italy is expected to tackle the rise in biopharmaceutical material demand, specifically for GLP-1s.

The Netherlands plant is expected to provide solutions that can help further the development of advanced therapies. 

Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.

With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.

The CDMO will run the active pharmaceutical ingredient pilot plant in Sandwich, UK, along with development laboratories. 

The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.

The facility, company says, will be its first that covers end-to-end ADC production.